Daniel Char - 30 Nov 2022 Form 4 Insider Report for ImmunoGen, Inc.

Reporting relationship: SVP & CHIEF LEGAL OFFICER
Issuer ticker: N/A
Reported as of: 30 Nov 2022
Net transaction value: +$2,076,000
SEC form: 4
Accepted by SEC: 30 Nov 2022, 16:16:17 UTC
Prior SEC filing: 30 Nov 2022
Next SEC filing: 05 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Renee Lentini, Attorney-in-Fact

Key filing fact

Daniel Char filed Form 4 for ImmunoGen, Inc. on 30 Nov 2022.

Key facts

This page summarizes Daniel Char's Form 4 filing for ImmunoGen, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Nov 2022, 16:16.

Change

Previous filing in this sequence was filed on 30 Nov 2022.
Current net transaction value: +$2,076,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMGN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $2,076,000
Shares: +400,000
Change %
Price: $5.19
Shares after: 400,000
Date: 30 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $5.19
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.